Atara Biotherapeutics, Inc.
0 products tracked · names used in filings: Atara Biotherapeutics, Inc.
Upcoming milestones
tab-cel: PDUFA target action date (EBV+ post-transplant lymphoproliferative disease (PTLD) after at least one prior therapy)
Atara Biotherapeutics, Inc. (ATRA); tabelecleucel; BLA; status: set; "Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027 Approval of BLA would unlock a $31 Million milestone payment from Pierre Fabre Laboratories Nine-month year over year reduction in costs and…"; filed 2026-11-10 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.